1459 GMT - AstraZeneca's trial results for breast cancer pill Camizestrant are a material positive surprise and clear the first of its major late-stage catalysts for this year, Barclays analysts say in a note. The British pharma giant's results showed the drug candidate helped patients live for longer without their disease worsening. AstraZeneca guides for a more than $5 billion peak sales potential, whereas Barclays anticipates $3.6 billion. The company indicated it would release most key results in 2H, leading to the analysts expecting publication in the middle of the summer. Shares are up 0.1% at 119.46 pounds.(helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 26, 2025 09:59 ET (14:59 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。